INTEGRATED BIOPHARMA, INC. (INBP) Total liabilities 2018–2026
INTEGRATED BIOPHARMA, INC. (INBP) total liabilities at each fiscal year-end, per SEC filings.
$7.7MFY2026 · since FY2018: $19.8M → $7.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $7.7M | +67.3% |
| FY2025 | $4.6M | -34.2% |
| FY2024 | $7.0M | +6.1% |
| FY2023 | $6.6M | -1.6% |
| FY2022 | $6.7M | -39.9% |
| FY2021 | $11.1M | -34.2% |
| FY2020 | $16.9M | -5.7% |
| FY2019 | $17.9M | -9.6% |
| FY2018 | $19.8M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More INBP financial trends
INBP RevenueINBP Net incomeINBP Net marginINBP Gross profitINBP Gross marginINBP Operating incomeINBP Operating marginINBP Operating cash flowINBP Free cash flowINBP Capital expendituresINBP Return on equityINBP Stock buybacksINBP Dividends paidINBP Total assetsINBP Shareholders’ equityINBP overview →